Subject    :    [2019 Apr;43(2)] Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Writer KDA
Date 2019-04-18 10:28:29 Hit 858
LINK URL https://e-dmj.org/search.php?where=aview&id=10.4093/dmj.2019.0034&code=2004DMJ&vmode=FULL (Click 15)
Diabetes Metab J. 2019 Apr;43(2):127-143. English.
Published online Apr 15, 2019.  https://doi.org/10.4093/dmj.2019.0034 
Copyright © 2019 Korean Diabetes Association
   
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kyung-Soo Kim,1 Byung-Wan Lee,2 Yong Jin Kim,3 Dae Ho Lee,4 Bong-Soo Cha,2 and Cheol-Young Park5
1Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
2Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
3Department of Surgery, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
4Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
5Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Corresponding author: Byung-Wan Lee. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Email: bwanlee@yuhs.ac Corresponding author: Cheol-Young Park. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea. Email: cydoctor@chol.com 
 
Received February 19, 2019; Accepted March 19, 2019.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

   
Keywords:
Diabetes mellitusDiabetes mellitus, type 2Fatty liverLiver diseasesMetabolic diseasesNon-alcoholic fatty liver diseaseTherapeutics
 
 

Articles - Reviews in DMJ
No. Subject Date Hit ↑
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 58
Notice : [2019 Apr;43(2)] Associations between Breastfeeding and Type 2 Diabetes Mellitus and Glycemic Control in Parous Women: A Nationwide, Population-Based Study [2019 Apr;43(2)] Associations between Breastfeeding and Type 2 Diabe... 2019-04-18 1,137
Notice : [2019 Apr;43(2)] Increased Nociceptive Responses in Streptozotocin-Induced Diabetic Rats and the Related Expression of Spinal NR2B Subunit of N-Methyl-D-Aspartate Receptors [2019 Apr;43(2)] Increased Nociceptive Responses in Streptozotocin-I... 2019-04-18 873
Notice : [2019 Apr;43(2)] The Risk of Myocardial Infarction and Ischemic Stroke According to Waist Circumference in 21,749,261 Korean Adults: A Nationwide Population-Based Study [2019 Apr;43(2)] The Risk of Myocardial Infarction and Ischemic Stro... 2019-04-18 890
Notice : [2019 Apr;43(2)] Myricetin Protects Against High Glucose-Induced β-Cell Apoptosis by Attenuating Endoplasmic Reticulum Stress via Inactivation of Cyclin-Dependent Kinase 5 [2019 Apr;43(2)] Myricetin Protects Against High Glucose-Induced ... 2019-04-18 840
Notice : [2019 Apr;43(2)] Association between Changes in Anthropometric Indices and in Fasting Insulin Levels among Healthy Korean Adolescents: The JS High School Study [2019 Apr;43(2)] Association between Changes in Anthropometric Indic... 2019-04-18 853
Notice : [2019 Apr;43(2)] Discrepancies between Glycosylated Hemoglobin and Fasting Plasma Glucose for Diagnosing Impaired Fasting Glucose and Diabetes Mellitus in Korean Youth and Young Adults [2019 Apr;43(2)] Discrepancies between Glycosylated Hemoglobin and F... 2019-04-18 877
Notice : [2019 Apr;43(2)] Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors [2019 Apr;43(2)] Predictors of the Therapeutic Efficacy and Consider... 2019-04-18 846
Notice : [2019 Apr;43(2)] Metabolic Consequences of Obstructive Sleep Apnea Especially Pertaining to Diabetes Mellitus and Insulin Sensitivity [2019 Apr;43(2)] Metabolic Consequences of Obstructive Sleep Apnea E... 2019-04-18 853
Notice : [2019 Apr;43(2)] Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment [2019 Apr;43(2)] Nonalcoholic Fatty Liver Disease and Diabetes: Part... 2019-04-18 858
283 [2017 Jun;41(3)] The Effect of 12 Weeks Aerobic, Resistance, and Com... 2017-07-06 9,021
282 [2017 Jun;41(3)] Satisfaction Survey on Information Technology-Based... 2017-07-06 8,939
281 [2017 Jun;41(3)] Impact of Gender on the Association between Low Ser... 2017-07-06 8,719
280 [2017 Jun;41(3)] Comparison of Antidiabetic Regimens in Patients wit... 2017-07-06 8,524
279 [2017 Jun;41(3)] Physician-Directed Diabetes Education without a Med... 2017-07-06 8,420
278 [2017 Apr;41(2)] Association between Blood Mercury Level and Viscera... 2017-07-06 8,390
277 [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in... 2017-07-06 8,371
276 [2017 Apr;41(2)] Diabetes Camp as Continuing Education for Diabetes ... 2017-07-06 8,343
275 [2017 Apr;41(2)] Role of NO/VASP Signaling Pathway against Obesity-R... 2017-07-06 8,332
274 [2017 Jun;41(3)] Diabetes Prevention in Australia: 10 Years Results ... 2017-07-06 8,301

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.